Zobrazeno 1 - 10
of 440
pro vyhledávání: '"Sjoerd H Van der Burg"'
Autor:
Diane van der Woude, Theo Rispens, Catharina M Korse, Sjoerd H van der Burg, Ellen Kapiteijn, John B A G Haanen, Winan J van Houdt, Els M E Verdegaal, Marij J P Welters, Jessica S W Borgers, Tineke J van Wesemael, Johannes V van Thienen, Kyra A Gelderman, Dirk J A R Moes
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 6 (2024)
Introduction Treatment with the immune checkpoint inhibitor anti-programmed cell death protein-1 (PD-1) often causes immune-related adverse events (irAEs). Since irAEs resemble autoimmune diseases, autoantibodies might play a role and could potential
Externí odkaz:
https://doaj.org/article/9616b7f6fe8b499baab93acfee17c709
Autor:
Sjoerd H van der Burg, Michael T Lotze
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 6 (2024)
Externí odkaz:
https://doaj.org/article/23dbf594ea28419ab71a6a1d3ba78c3b
Autor:
Judith R Kroep, Sjoerd H van der Burg, Marten Visser, Linda de Bruin, Pauline Meij, Inge Roozen, Els M E Verdegaal, Caroline E van der Minne, Marij J P Welters, Saskia J Santegoets, Nikki M Loof, Sanne Boekestijn, Pita M de Kok, Inge M Westra
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 11 (2023)
Background The presence of T cells and suppressive myeloid cells in epithelial ovarian cancer (EOC) correlate with good and bad clinical outcome, respectively. This suggests that EOC may be sensitive to adoptive cell therapy with autologous tumor-inf
Externí odkaz:
https://doaj.org/article/23ac6018768843a28d87a7fb513a2cca
Autor:
Sjoerd H van der Burg, Suzanne van Duikeren, Ramon Arens, Cornelis J M Melief, Tetje C van der Sluis, Ward Vleeshouwers, Floortje J van Haften, Iris N Pardieck, J Fréderique de Graaf, Koen van der Maaden
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 11 (2023)
Background The survival of patients with cervical cancer who are treated with cisplatin in conjunction with the topoisomerase I inhibitor topotecan is enhanced when compared with patients treated with only one of these chemotherapeutics. Moreover, ci
Externí odkaz:
https://doaj.org/article/103d84188abd4c6ba820be7b2a53081b
Autor:
Sjoerd H van der Burg, Thorbald van Hall, Camilla Labrie, Marit J van Elsas, Pornpimol Charoentong, Jordi J C van Stigt Thans, Anders Etzerodt
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 3 (2023)
Background Primary and secondary resistance is a major hurdle in cancer immunotherapy. Therefore, a better understanding of the underlying mechanisms involved in immunotherapy resistance is of pivotal importance to improve therapy outcome.Method Here
Externí odkaz:
https://doaj.org/article/37f0719b90c040e2aafd9442fcd7cedf
Autor:
Sjoerd H van der Burg, Rebekka Duhen, Thomas Duhen, Marieke E Ijsselsteijn, Ruud van der Breggen, Koen C M J Peeters, Noel F C C de Miranda, Els M E Verdegaal, Dina Ruano, Manon van der Ploeg, Jitske van den Bulk, Arantza Fariña-Sarasqueta
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 2 (2023)
Background Expression of CD103 and CD39 has been found to pinpoint tumor-reactive CD8+ T cells in a variety of solid cancers. We aimed to investigate whether these markers specifically identify neoantigen-specific T cells in colorectal cancers (CRCs)
Externí odkaz:
https://doaj.org/article/a80924796f3f43ca978f61b4c5f9bebf
Autor:
Natasja Hendriks, Sjoerd H van der Burg, Ziena Abdulrahman, Noel F C C de Miranda, Edith M G van Esch, Peggy J de Vos van Steenwijk, Antonios Somarakis, Arnold J Kruse, Anna J M van de Sande, Heleen J van Beekhuizen, Jurgen M J Piek, Loes F S Kooreman, Brigitte F M Slangen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 11 (2022)
Background The complete response rate of cervical high-grade squamous intraepithelial lesion (cHSIL) patients to imiquimod immunotherapy is approximately 60%. Consequently, many patients are exposed to unnecessary adverse effects of imiquimod. On the
Externí odkaz:
https://doaj.org/article/ae2985823b1043c281f9a4695715eadb
Autor:
Hans Gelderblom, Sjoerd H van der Burg, Ferry Ossendorp, Peggy J de Vos van Steenwijk, Mariette I E van Poelgeest, Inge Roozen, Willem-Jan Krebber, Cornelis J M Melief, Frank M Speetjens, Marij J P Welters, Nikki M Loof, Sanne Boekestijn, Catharina A H Janssen, Marije Slingerland, Gijs G Zom, A Rob P M Valentijn, Nico J Meeuwenoord, Gijs A van der Marel, Dmitri V Filippov
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 10 (2022)
Background Amplivant is a molecularly optimized Toll-like receptor 2 ligand that can be covalently conjugated to tumor peptide antigens. In preclinical models, amplivant-adjuvanted synthetic long peptides (SLPs) strongly enhanced antigen presentation
Externí odkaz:
https://doaj.org/article/116d0102ba984134b3b45409c8b1b84b
Autor:
Rob C Hoeben, Sjoerd H van der Burg, Marjolein Sluijter, Thorbald van Hall, Joke M M Den Haan, Camilla Labrie, Christianne Groeneveldt, Priscilla Kinderman, Diana J M van den Wollenberg, Nadine van Montfoort, Lisa Griffioen, Jordi J C van Stigt Thans
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 7 (2022)
Background Many solid tumors do not respond to immunotherapy due to their immunologically cold tumor microenvironment (TME). We and others found that oncolytic viruses (OVs), including reovirus type 3 Dearing, can enhance the efficacy of immunotherap
Externí odkaz:
https://doaj.org/article/3366d822d5c7405c92a4c4b02eb41013
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 7 (2022)
Myeloid immune cells are frequently present in the tumor environment, and although they can positively contribute to tumor control they often negatively impact anticancer immune responses. One way of inhibiting the positive contributions of myeloid c
Externí odkaz:
https://doaj.org/article/9e5b433f0e75451db7985f05e309a250